Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Economics of monitoring antiretroviral therapy.

Mermin J, Granich R.

Lancet Infect Dis. 2013 Jul;13(7):560-1. doi: 10.1016/S1473-3099(13)70105-1. Epub 2013 Apr 18. No abstract available.

PMID:
23602085
2.

Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.

Kumarasamy N, Krishnan S.

Curr Opin HIV AIDS. 2013 Nov;8(6):586-90. doi: 10.1097/COH.0000000000000004. Review.

PMID:
24100872
3.

HIV therapeutics: points from the recent literature.

Laurence J.

AIDS Read. 2003 Jul;13(7):305, 307. Review. No abstract available.

PMID:
12889448
4.

[Once-a-day highly active antiretroviral therapy. Present or future?].

Pulido F, Hernando A.

Med Clin (Barc). 2003 Sep 13;121(8):304-9. Review. Spanish. No abstract available.

PMID:
14499087
5.

New antiretroviral drugs and approaches to HIV treatment.

Paredes R, Clotet B.

AIDS. 2003;17 Suppl 4:S85-96. Review. No abstract available.

PMID:
15080184
6.

Current uses and future hopes for clinical pharmacology in the management of HIV infection.

Back D, Khoo S, Maher B, Gibbons S.

HIV Med. 2000 Jul;1 Suppl 2:12-7. Review. No abstract available.

7.

Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy.

Palmer S.

Curr Opin HIV AIDS. 2013 Mar;8(2):87-92. doi: 10.1097/COH.0b013e32835d80af. Review.

PMID:
23314906
8.

The continuing evolution of HIV therapy.

Boyle BA.

AIDS Read. 2003 Dec;13(12):576-8, 582. Review. No abstract available.

PMID:
14959692
9.

Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.

Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, Clotet B, Huffam S, Boucher CA, Cooper DA, Schapiro JM.

AIDS. 2008 Oct 18;22(16):2053-67. doi: 10.1097/QAD.0b013e328309520d. Review. No abstract available.

PMID:
18753937
10.

[Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].

Gemeinsame Erklärung der Deutschen AIDS-Gesellschaft (DAIG); Osterreichischen AIDS-Gesellschaft (OAG).

Dtsch Med Wochenschr. 2009 Jan;134 Suppl 1:S4-15. doi: 10.1055/s-0028-1123965. Epub 2009 Jan 26. Review. German. No abstract available.

PMID:
19172554
11.

Highly active antiretroviral therapy in neonates and young infants.

Bell GS.

Neonatal Netw. 2004 Mar-Apr;23(2):55-64. Review.

PMID:
15077862
12.

Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs.

Kiser JJ, Anderson PL, Gerber JG.

Curr HIV/AIDS Rep. 2005 Jun;2(2):61-7. Review.

PMID:
16091250
13.

HIV drug resistance and nursing practice.

Funesti Esch J, Frank SV.

Am J Nurs. 2001 Jun;101(6):30-5; quiz 36. Review. No abstract available.

PMID:
11441759
14.

Antiretroviral roll-out: the problem of second-line therapy.

Boyd M, Emery S, Cooper DA.

Lancet. 2009 Jul 18;374(9685):185-6. doi: 10.1016/S0140-6736(09)61313-1. Review. No abstract available. Erratum in: Lancet. 2009 Oct 3;374(9696):1148.

PMID:
19616706
15.

Patients who want to stop their medications: treatment interruptions in HIV infection.

Ball SC.

AIDS Read. 2003 Jul;13(7):317-9, 324, 342. Review. No abstract available.

PMID:
12889449
16.

Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program.

Mind Exchange Working Group.

Clin Infect Dis. 2013 Apr;56(7):1004-17. doi: 10.1093/cid/cis975. Epub 2012 Nov 21.

Supplemental Content

Support Center